Literature DB >> 22154518

A microRNA guide for clinicians and basic scientists: background and experimental techniques.

Bianca C Bernardo1, Fadi J Charchar, Ruby C Y Lin, Julie R McMullen.   

Abstract

MicroRNAs (miRNAs) are short non-coding RNA molecules that are approximately 22 nucleotides in length. In the last 10 years, miRNA research and discovery has advanced at a rapid rate. This review provides a brief overview of the discovery and biology of miRNAs, and summarises some of the experimental techniques used for isolation, detection, target prediction, and regulation of miRNAs. We also outline experimental workflows for investigators new to the field, and discuss the diagnostic and therapeutic application of miRNAs. Copyright Â
© 2011 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.

Mesh：

Substances：

Year:  2011        PMID： 22154518     DOI： 10.1016/j.hlc.2011.11.002

Source DB:  PubMed          Journal:  Heart Lung Circ        ISSN： 1443-9506            Impact factor:   2.975


  33 in total

Review 1.  miRNA analysis for the assessment of exercise and amino acid effects on human skeletal muscle.

Authors:  Stefan M Pasiakos; James P McClung
Journal:  Adv Nutr       Date:  2013-07-01       Impact factor: 8.701

2.  Noncoding RNAs regulating cardiac muscle mass.

Authors:  Glenn D Wadley; Séverine Lamon; Sarah E Alexander; Julie R McMullen; Bianca C Bernardo
Journal:  J Appl Physiol (1985)       Date:  2018-12-20

3.  Sex differences in response to miRNA-34a therapy in mouse models of cardiac disease: identification of sex-, disease- and treatment-regulated miRNAs.

Authors:  Bianca C Bernardo; Jenny Y Y Ooi; Aya Matsumoto; Yow Keat Tham; Saloni Singla; Helen Kiriazis; Natalie L Patterson; Junichi Sadoshima; Susanna Obad; Ruby C Y Lin; Julie R McMullen
Journal:  J Physiol       Date:  2016-07-20       Impact factor: 5.182

Review 4.  MicroRNA208 family in cardiovascular diseases: therapeutic implication and potential biomarker.

Authors:  Ying Huang; Jun Li
Journal:  J Physiol Biochem       Date:  2015-04-04       Impact factor: 4.158

Review 5.  Exercise in Heart Failure-What Is the Optimal Dose to Improve Pathophysiology and Exercise Capacity?

Authors:  Michael Johannes Schindler; Volker Adams; Martin Halle
Journal:  Curr Heart Fail Rep       Date:  2019-08

6.  Therapeutic potential of targeting microRNAs to regulate cardiac fibrosis: miR-433 a new fibrotic player.

Authors:  Jenny Y Y Ooi; Bianca C Bernardo; Julie R McMullen
Journal:  Ann Transl Med       Date:  2016-12

Review 7.  MicroRNA and MET in lung cancer.

Authors:  Matteo Brighenti
Journal:  Ann Transl Med       Date:  2015-04

8.  Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function.

Authors:  Bianca C Bernardo; Xiao-Ming Gao; Catherine E Winbanks; Esther J H Boey; Yow Keat Tham; Helen Kiriazis; Paul Gregorevic; Susanna Obad; Sakari Kauppinen; Xiao-Jun Du; Ruby C Y Lin; Julie R McMullen
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-09       Impact factor: 11.205

9.  Identification of miR-34 regulatory networks in settings of disease and antimiR-therapy: Implications for treating cardiac pathology and other diseases.

Authors:  Jenny Y Y Ooi; Bianca C Bernardo; Saloni Singla; Natalie L Patterson; Ruby C Y Lin; Julie R McMullen
Journal:  RNA Biol       Date:  2016-04-28       Impact factor: 4.652

Review 10.  From Bench to Bedside: New Approaches to Therapeutic Discovery for Heart Failure.

Authors:  Bianca C Bernardo; Burns C Blaxall
Journal:  Heart Lung Circ       Date:  2016-01-19       Impact factor: 2.975
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.